TABLE 1

Diagnostic accuracy measured by likelihood ratios

Specimen,c culture duration (days) or 16S rRNA sequencingNo. of cases with a positive test/no. of cases testedLRa
PJI (n = 42)AF (n = 66)Positive (95% CI)Negative (95% CI)
5-STB, 631/420/66Infinityb0.3 (0.2–0.4)
5-STB, 1437/420/66Infinity0.1 (0.05–0.3)
JF, 626/391/5738 (5–269)0.3 (0.2–0.5)
JF, 1434/392/5624 (6–96)0.1 (0.06–0.3)
PC, 624/371/6039 (5–276)0.4 (0.2–0.6)
PC, 1433/375/6011 (5–25)0.1 (0.05–0.3)
SW (in situ), 69/320/59Infinity0.7 (0.6–0.9)
SW (in situ), 1416/322/5915 (4–60)0.5 (0.4–0.7)
BB, 69/320/54Infinity0.8 (0.7–0.9)
BB, 1413/321/5422 (3–160)0.6 (0.5–0.8)
Periprosthetic tissue, 16S rRNA sequencing8/320/53Infinity0.8 (0.6–0.9)
Synovial fluid, 16S rRNA sequencing25/351/6546 (7–328)0.3 (0.2–0.5)
PC, 16S rRNA sequencing32/371/6455 (8–389)0.1 (0.06–0.3)
SW (in situ), 16S rRNA sequencing15/344/526 (2–16)0.6 (0.4–0.8)
BB, 16S rRNA sequencing4/292/473 (0.6–17)0.9 (0.8–1.0)
  • a Positive describes how probability of infection shifts with positive results, and negative describes how probability of infection wanes with negative results. CI, confidence interval.

  • b An incalculably large number.

  • c For abbreviations of specimen types, see the text.